Usefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorder
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Han, Changsu | - |
dc.contributor.author | Lee, Moon-Soo | - |
dc.contributor.author | Pae, Chi-Un | - |
dc.contributor.author | Ko, Young-Hoon | - |
dc.contributor.author | Patkar, Ashwin A. | - |
dc.contributor.author | Jung, In-Kwa | - |
dc.date.accessioned | 2021-09-09T17:11:18Z | - |
dc.date.available | 2021-09-09T17:11:18Z | - |
dc.date.created | 2021-06-10 | - |
dc.date.issued | 2007-08-15 | - |
dc.identifier.issn | 0278-5846 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/125732 | - |
dc.description.abstract | This study aimed to assess the safety, tolerability, efficacy, and compliance of a risperidone long-acting injection (RLAI) formulation for the maintenance treatment of stabilized bipolar patients. A prospective, open-label trial of RLAI was conducted for 12 months. Stable bipolar patients (n=11) were switched from their existing oral antipsychotic agents to RLAI, and injections were given every 2 weeks. The assessments were performed at baseline and at 6 and 12 months of treatment by using the Young Mania Rating Scale (YMRS), Clinical Global Impressions - Severity of Illness (CGI-S) scale, 17-item Hamilton Rating Scale for Depression (HAM-D), Brief Psychiatric Rating Scale (BPRS), and Extrapyramidal Symptom Rating Scale (ESRS). The satisfaction levels of subjects were evaluated at the end of the study period using a 10-point visual analog scale. Ten patients (90.9%) completed the trial, and no significant changes were seen in the YMRS, HAM-D, and BPRS scores throughout the study. CGI-S and ESRS scores were significantly decreased from the baseline to the post-12-month treatment score. Relapses were not reported by any of the participants. This result indicates that RLAI may be beneficial in the maintenance therapy of stable bipolar patients; however, an adequately powered, randomized, placebo-controlled trial is necessary to draw a definite conclusion about the role of RLAI in the maintenance treatment of bipolar patients. (C) 2007 Elsevier Inc. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | PERGAMON-ELSEVIER SCIENCE LTD | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | RATING-SCALE | - |
dc.subject | ATYPICAL ANTIPSYCHOTICS | - |
dc.subject | TERM TREATMENT | - |
dc.subject | I-DISORDER | - |
dc.subject | MANIA | - |
dc.subject | ARIPIPRAZOLE | - |
dc.subject | EFFICACY | - |
dc.subject | TRIAL | - |
dc.subject | SCHIZOPHRENIA | - |
dc.title | Usefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorder | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Moon-Soo | - |
dc.identifier.doi | 10.1016/j.pnpbp.2007.04.017 | - |
dc.identifier.scopusid | 2-s2.0-34447563990 | - |
dc.identifier.wosid | 000249187300009 | - |
dc.identifier.bibliographicCitation | PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, v.31, no.6, pp.1219 - 1223 | - |
dc.relation.isPartOf | PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY | - |
dc.citation.title | PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY | - |
dc.citation.volume | 31 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1219 | - |
dc.citation.endPage | 1223 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Psychiatry | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.relation.journalWebOfScienceCategory | Neurosciences | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Psychiatry | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | RATING-SCALE | - |
dc.subject.keywordPlus | ATYPICAL ANTIPSYCHOTICS | - |
dc.subject.keywordPlus | TERM TREATMENT | - |
dc.subject.keywordPlus | I-DISORDER | - |
dc.subject.keywordPlus | MANIA | - |
dc.subject.keywordPlus | ARIPIPRAZOLE | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | SCHIZOPHRENIA | - |
dc.subject.keywordAuthor | bipolar disorder | - |
dc.subject.keywordAuthor | long-acting injections | - |
dc.subject.keywordAuthor | maintenance | - |
dc.subject.keywordAuthor | risperidone | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.